Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Report Summary:
This exclusive report delivers a comprehensive structural and clinical risk assessment of ABL Bio, Inc. (KOSDAQ: 298380), a leading Korean biotech company specializing in bispecific antibody platforms. The analysis covers the company’s Grabody-T/B/Y patent families, FY2024 financial performance, licensing agreements with I-Mab, Sanofi, and the now-terminated IntoCell collaboration for ADC development.
Key sections include verified clinical trial data (ClinicalTrials.gov), FTO risk review post-Nexatecan, regulatory inconsistencies (notably ABL105), and technical strengths in immuno-oncology and neurodegenerative disease targeting.
Intended for:
Venture capital and family office investors in oncology biotech
Pharma business development, IP, and regulatory due diligence teams
Investment consultants or M&A advisors focused on APAC biotech
Stakeholders assessing ADC platform risks and licensing potential
Key Features:
✅ Audited under BBIU’s 5 Operational Laws
✅ Patent portfolio analysis across EP, WO, AU, US jurisdictions
✅ Clinical trial mapping with ASCO, AACR, and ESMO disclosures
✅ Strategic recommendations for investors and licensing partners
Note: This report is part of BBIU’s premium intelligence repository and adheres to strict traceability and regulatory coherence standards.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com
Report Summary:
This exclusive report delivers a comprehensive structural and clinical risk assessment of ABL Bio, Inc. (KOSDAQ: 298380), a leading Korean biotech company specializing in bispecific antibody platforms. The analysis covers the company’s Grabody-T/B/Y patent families, FY2024 financial performance, licensing agreements with I-Mab, Sanofi, and the now-terminated IntoCell collaboration for ADC development.
Key sections include verified clinical trial data (ClinicalTrials.gov), FTO risk review post-Nexatecan, regulatory inconsistencies (notably ABL105), and technical strengths in immuno-oncology and neurodegenerative disease targeting.
Intended for:
Venture capital and family office investors in oncology biotech
Pharma business development, IP, and regulatory due diligence teams
Investment consultants or M&A advisors focused on APAC biotech
Stakeholders assessing ADC platform risks and licensing potential
Key Features:
✅ Audited under BBIU’s 5 Operational Laws
✅ Patent portfolio analysis across EP, WO, AU, US jurisdictions
✅ Clinical trial mapping with ASCO, AACR, and ESMO disclosures
✅ Strategic recommendations for investors and licensing partners
Note: This report is part of BBIU’s premium intelligence repository and adheres to strict traceability and regulatory coherence standards.
Access Password
This document is password-protected.
To open it, use the company’s stock exchange ID number as the password.
🔐 Example: 6 digit
If you encounter any issues, contact us at yoonhwa.an@biopharmabusinessintelligenceunit.com